StockIQStockIQ.tech

STERIS plc (STE) Stock Analysis

--

Free AI-powered analysis and research for STERIS plc stock

Sector: Healthcare

STE snapshot

Data as of 3 Nov 2026 close. Updated daily.

Last close
232.04 USD (-0.56%)
52-week range
195.14 – 269.44
Position in range
50%
1-year change
-2.2%
Market cap (USD)
$22.6B
P/E (trailing)
27.9
RSI (14-day)
61
vs 200-day average
+3.4%
MACD
Above signal line
StockIQ score: 79/100 · Strongly positive signals

STERIS plc scores 79/100 on StockIQ's model, which reads as strongly positive signals overall. The price is above its 200-day average and at 50% of its 52-week range, down 2.2% over the past year. Latest reported figures show a profit margin of 13.3%, return on equity of 11.4% and revenue growth of +7.3%.

What is driving the score
  • Strong Uptrend: +12
  • MACD Bullish: +8
  • Good Profit Margin (13.3%): +5
  • Low Debt (0.28 D/E): +8
  • Above MA200: +4
  • Underperforming (-2.2% over 1 year): -5
  • Low Volume (0.4x): -3

Automated, general information only – not financial advice. Scores can be wrong. How the score works

Full STE report

STERIS plc (STE) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.

Analyze STE Now β†’

πŸ“° Latest Update

STERIS (STE) Dividend Reaffirms The Story As Undervalued Views Face A P E Reality

STERIS (STE) recently reaffirmed its dividend, signaling confidence in its financial stability despite facing challenges related to valuation perceptions. This move is significant for investors as it underscores the company's commitment to returning value to shareholders, potentially countering concerns about being undervalued in the current market. The dividend announcement may attract income-focused investors and bolster confidence in STE's long-term growth prospects.

Read full article β†’

History

People also watch

AMGN
Amgen Inc.
--
REGN
Regeneron Pharmaceuticals Inc.
--
GILD
Gilead Sciences Inc.
--
PACS
PACS Group, Inc.
--
CATX
Perspective Therapeutics, Inc.
--